BARCELONA—In people with primary progres- sive multiple sclerosis (MS), treatment with
ocrelizumab may significantly reduce the progression of clinical disability sustained for at least 12
weeks, compared with placebo, according to results
from a pivotal phase III study presented at the 31st
Congress of ECTRIMS. In the study, which is called
ORATORIO, clinical disability was measured by the
Expanded Disability Status Scale (EDSS).
Ocrelizumab is an investigational, humanized
monoclonal antibody designed to selectively target
CD20-positive B cells. CD20-positive B cells are a type
of immune cell thought to be a key contributor to
myelin damage and axonal damage. Preclinical studies
suggest that ocrelizumab binds to CD20 cell-surface
proteins expressed on certain B cells, but not on stem
cells or plasma cells, thus potentially preserving im-
portant functions of the immune system.
The ORATORIO trial was a randomized, double-blind, global multicenter study. Researchers administered placebo or 600 mg of ocrelizumab by IV infusion every six months to 732 people with primary
progressive MS. The doses of ocrelizumab were given as two 300-mg infusions two weeks apart. The
Volume 23, Number 11
Ocrelizumab May Reduce
Disability Progression in People
With Primary Progressive MS
Serving the Neurology Community Since 1993
FOLLOW US ON Find us on
continued on page 3
Noninvasive Brain Stimulation
4 May Spur Stroke Recovery
How Can Neurologists
12 Manage Essential Tremor?
How Prevalent Is
17 Complex Insomnia?
Research Is Enabling New
21 Trials in Huntington’s Disease
Several Variables May Identify
32 Preclinical Alzheimer’s Disease
Is Rivaroxaban a Safe Treatment
37 for Preventing Stroke?
Genetic Testing Can Improve
51 Pediatric Epilepsy Care
Inside This Issue